Transforming Life Sciences R&D: The Business Case for AI

Are you using AI in your R&D processes? Join the experts from the three different companies, Novartis, Gartner, and Causaly in this exclusive webinar to explore emerging tech, real-world AI applications, and a vision for the future of data-driven drug discovery.

Register Free: https://www.pharmexec.com/pe_w/life-sciences

Event Overview:

Join us in this gripping session where you will hear from experts at Novartis and Gartner as they discuss the increased adoption of AI in the life sciences industry and, in particular, the impact of AI on R&D processes.
AI is rapidly redefining how life sciences organizations approach R&D. As data volumes grow exponentially and precision medicine becomes the norm, traditional research methods can no longer keep pace. In this exclusive webinar, Gartner unveils its latest research “Hype Cycle for Life Sciences R&D, 2025” , highlighting transformative technologies including AI, multiomics, cloud, and digital trials that are critical for staying competitive. You'll also hear how Novartis is applying AI to real-world discovery workflows, and how Causaly’s AI platform enables faster, evidence-based decisions in research processes.

Key Learning Objectives:

• Understand the emerging technologies shaping life sciences R&D
• Learn how Novartis applies AI to accelerate discovery & decision-making
• Explore AI-powered solutions to transform R&D operations

Who Should Attend:

• R&D teams and leaders
• IT and AI Leaders
• Pharmaceutical companies
• Biotechnology companies

Speakers

Jeremy Jenkins
US Head of Discovery Sciences
Novartis

Jeremy Jenkins is the US Head of Discovery Sciences in Novartis Biomedical Research. He joined Novartis as a postdoc in 2003, following a postdoc at Harvard Medical School and a PhD in Molecular Genetics from The Ohio State University. He received the 2011 Corwin Hansch Award for contributions to the field of QSAR, and the 2017 Novartis Leading Scientist VIVA award for helping to develop the field of in silico chemical biology. His global research teams at Novartis focus on early drug discovery projects and enabling technologies for target ID and lead discovery. Currently, Jeremy is leading the AI For Target ID efforts.

Reuben Harwood
Director Analyst with Gartner's Healthcare

Reuben Harwood is a Director Analyst with Gartner's Healthcare and Life Sciences team. Reuben works with technology and business leaders to respond to rapid innovation at the intersection of science and technology. His research explores the rise generative AI, and accelerated use of AI more broadly, to advance drug and scientific discovery. Reuben leads Gartner's coverage of genomics, multiomics, cell and gene therapies, synthetic biology and precision medicine. With mainstream adoption of AI to solve the industry's greatest challenges, healthcare and life science leaders must resolve data silos and bottlenecks, and Reuben's work helps leaders address these issues in their organizations.

Register Free: https://www.pharmexec.com/pe_w/life-sciences